Cetuximab for Head and Neck Cancer
Cetuximab (Erbitux) is now approved for use in combination with radiation therapy to treat patients with un-resectable squamous cell cancer of the head and neck. It is manufactured by ImClone Systems and will be distributed and marketed by Bristol-Myers Squibb. prevacid drug
This is the first drug approved for head and neck cancer that has shown survival benefits for patients. It delayed tumor growth when used with radiation and helped shrink tumors after they no longer responded to platinum-based therapy.
